Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer.

Peter A Kaufman,Hans Wildiers,Gilles Freyer,Margaret Kemeny,Anthony Gonçalves,Guy Jerusalem,Alison Stopeck,Nandagopal Vrindavanam,Florence Dalenc,Nuwan Nanayakkara,Benjamin Wu,Cheryl A Pickett

Clinical Breast Cancer（2019）

引用 7|浏览36

暂无评分

摘要

This phase 1b study showed that trebananib was tolerated with manageable AEs at a dose up to 30 mg/kg weekly. Trebananib demonstrated anticancer activity, as indicated by objective response and duration of response.

查看译文

关键词

AMG 386,Angiogenesis,Angiopoietin,HER2 positive

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要